Aligos Therapeutics, Inc. (ALGS) stock
ALGSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 9/3053% below fair value
$1.36−0.30 (-18.07%)
Close on Nov 17, 2026Market cap $16.99MP/E –Yield –
Aligos Therapeutics total debt
Total debt is short-term plus long-term borrowings on the balance sheet at the end of each period.
No total debt figures for Aligos Therapeutics
Aligos Therapeutics has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.
See a number that looks wrong?